HIV/AIDS still remains one of the biggest health challenges worldwide. With more than 37 million people living with HIV globally, developing new and effective treatment options continues to be a priority. Integrase inhibitors are an important new class of antiretroviral drugs that work by blocking the enzyme HIV integrase.
How do Integrase Inhibitors Work?
To understand how integrase inhibitors are effective against HIV, it's important to first know how the HIV life cycle works. After HIV enters and infects a host cell, it begins replicating by generating DNA from its RNA genetic material. This process of reverse transcription produces double-stranded HIV DNA. A key viral enzyme called integrase is then needed to insert this HIV DNA into the host cell's genome, where it can continue replicating and producing new virus particles.
Integrase Inhibitors work by blocking the integrase enzyme from performing its function of integrating the HIV DNA into the host cell's chromosomes. Without integration, the virus is unable to establish a persistent infection or replicate itself. The isolated HIV DNA is eventually degraded by the cell’s natural DNA repair processes. This mechanism of action makes integrase inhibitors a unique and important tool in suppressing and controlling HIV viral loads in infected individuals.
Approved Integrase Inhibitors Drugs
There are currently three integrase inhibitor drugs that have been approved by regulatory agencies like the FDA for clinical use:
Raltegravir (Isentress) - Developed by Merck, raltegravir was the first in class integrase inhibitor approved in 2007. It demonstrated good efficacy and tolerability in clinical trials.
Elvitegravir (Vitekta) - Developed jointly by Gilead Sciences and Janssen, elvitegravir was approved in 2012. It is primarily used as part of fixed-dose combination therapies.
Bictegravir (Biktarvy) - Developed by Gilead Sciences, bictegravir was approved in 2018. Clinical trials demonstrated it to be as effective as existing drugs with a higher resistance barrier and fewer side effects.
All three drugs have demonstrated highly significant reductions in viral loads when used as part of combination antiretroviral therapy (cART). They have become important components of preferred first-line and switch HIV treatment regimens.
Benefits of Integrase Inhibitors
Compared to older drug classes like nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs) and non-nucleoside reverse transcriptase inhibitors (NNRTIs), integrase inhibitors offer several clinical advantages:
- Potent Viral Suppression: Integrase inhibitors consistently deliver rapid and sustained viral suppression to undetectable levels in the vast majority of patients. This translates to positive health outcomes.
- High Genetic Barrier: They are less prone to the development of resistance mutations compared to other drug classes. This durably retains their effectiveness over time and across patient populations.
- Fewer Side Effects: So far, integrase inhibitors demonstrate a relatively favorable tolerability and safety profile. Adverse effects are mostly mild to moderate in severity.
- Simpler Dosing: Many integrase inhibitor regimens require just one pill once daily. This promotes excellent treatment adherence which is critical for viral suppression.
- Formulation Flexibility: They can be formulated into single-tablet regimens as well as fixed-dose combinations with other antiretrovirals. This enhances convenience.
Role in Ending HIV Pandemic
With their potent efficacy, high genetic barrier and tolerable safety profiles, integrase inhibitors are increasingly becoming the treatment of choice for both initial and subsequent lines of HIV therapy. Their use in long-acting injectable formulations also holds promise for improving adherence to treatment, especially in resource-limited areas.
Integrase inhibitors represent a major advance over earlier drug classes. When scaled up as preferred first-line options globally, they can help push the rate of viral suppression to even higher levels needed to curb ongoing HIV transmission at a population level. Along with other prevention strategies, widespread use of these drugs offers real hope that an “AIDS-free generation” may one day become a reality. Continued research into next-generation compounds will also help combat emerging resistance threats and expand our toolbox against HIV.
Integrase inhibitors have transformed HIV treatment outcomes and established themselves as essential components of modern antiretroviral regimens. Their excellent efficacy profile further supports an optimally suppressive approach to treatment as prevention of new infections. Global access to these innovative drugs remains integral to eventually overcome the HIV pandemic through scientific means.
Get more insights on Integrase Inhibitors
The Global Salmon Calcitonin Market Report is prepared to club all the essential market details such as market size, share, value, growth, restraints, challenges, and opportunities during the study period of 2020-2025.
The data presented in this report has been gathered on the basis of historical data, primary interviews and expert's estimation of future trends.
The report also covers regional assessment which has been conducted globally.
The detailed content of the market study ensures intellectual insights given a better understanding of the untapped opportunities in the market.This report studies the global market size of Salmon Calcitonin in key regions like North America, Europe, Asia Pacific, Central & South America and Middle East & Africa, focuses on the consumption of Salmon Calcitonin in these regions.Access Full Report with Table of Contents @ https://www.decisiondatabases.com/ip/5890-salmon-calcitonin-professional-industry-survey-market-reportThe following manufacturers are covered in this report, with sales, revenue, market share for each company:NovartisSanofiMylan PharmaceuticalsApotexUpsher-Smith LaboratoriesFerring PharmaceuticalsPar PharmaceuticalTorrentSun PharmaceuticalUnited Biotech (P) Limited.Shanghai Soho-Yiming PharmaceuticalsSalmon Calcitonin market size by TypeCalcitonin Salmon Nasal SprayCalcitonin Salmon InjectionSalmon Calcitonin market size by ApplicationsHospital PharmaciesRetail PharmaciesOnline PharmaciesMarket size by RegionNorth AmericaUnited StatesCanadaMexicoAsia-PacificChinaJapanSouth KoreaIndiaDownload Free Sample Report of Global Salmon Calcitonin Market @ https://www.decisiondatabases.com/contact/download-sample-5890The study objectives of this report are:To study and analyze the global Salmon Calcitonin market size (value & volume) by company, key regions, products and end user, breakdown data from 2014 to 2018, and forecast to 2025.To understand the structure of Salmon Calcitonin market by identifying its various subsegments.To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).Focuses on the key global Salmon Calcitonin companies, to define, describe and analyze the sales volume, value, market share, market competition landscape and recent development.To project the value and sales volume of Salmon Calcitonin submarkets, with respect to key regions.To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.Purchase full Global Salmon Calcitonin Market Research Report @ https://www.decisiondatabases.com/contact/buy-now-5890Other Reports by DecisionDatabases.com:Global Salmon Sausage Market Insights, Forecast to 2025Global Salmon Fish Market Insights, Forecast to 2025About Us:DecisionDatabases.com is a Global business research report provider, enriching decision makers and strategists with qualitative statistics.
DecisionDatabases.com is proficient in providing syndicated research Reports, customized research reports, company profiles and industry databases across multiple domains.Our expert research analysts have been trained to map client’s research requirements to the correct research resource leading to a distinctive edge over its competitors.
We provide intellectual, precise and meaningful data at a lightning speed.For More Details:DecisionDatabases.comE-Mail: [email protected]: +91-90-28-057900Web: https://www.decisiondatabases.com/
The global psoriasis treatment market is expected to rise with an impressive CAGR and generate the highest revenue by 2026.
The report is titled "Psoriasis Treatment Market Size, Share and Global Trend By Drug Class (TNF Inhibitors, Interleukins, Others), By Type (Plaque Psoriasis, Psoriatic Arthritis, Others), By Route of Administration (Oral, Parenteral, Topical), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online pharmacies), and Geography Forecast till 2026".
The report discusses research objectives, research scope, methodology, timeline and challenges during the entire forecast period.
It also offers an exclusive insight into various details such as revenues, market share, strategies, growth rate, product & their pricing by region/country for all major companies.For more information, Get sample pdf @ https://www.fortunebusinessinsights.com/enquiry/request-sample-pdf/psoriasis-treatment-market-100600The report provides a 360-degree overview of the market, listing various factors restricting, propelling, and obstructing the market in the forecast duration.
The report also provides additional information such as interesting insights, key industry developments, detailed segmentation of the market, list of prominent players operating in the market, and other psoriasis treatment market trends.
The report is available for sale on the company website.Leading Players operating in the Psoriasis Treatment Market are:Merck & Co., Inc.,LEO Pharma A/S,Pfizer Inc.,Sun Pharmaceutical Industries Ltd,AbbVie Inc.,UCB S.A.,Amgen Inc.,Johnson & Johnson Services, Inc.,Eli Lilly and Company,Rising Prevalence of Plaque Psoriasis to Increase Demand for Treatment, Boosting MarketOne of the major factor boosting the global psoriasis treatment market is the increasing prevalence of the disease itself.
